Patient monitoring should include: Baseline lipid panel, hemoglobin A1c, and liver function tests Blood pressure monitoring (GLP-1 agents typically reduce systolic BP by 3-5 mmHg) [10] Assessment for gastrointestinal adverse effects during dose titration Evaluation for contraindications (personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2) [1] [3] Monitoring for gallbladder disease (increased risk with rapid weight loss) In patients with diabetes and retinopathy, monitoring for worsening eye symptoms, particularly with rapid glycemic improvement Renal function assessment, especially if severe gastrointestinal symptoms cause dehydration Patients should seek immediate medical attention for severe abdominal pain, which may indicate pancreatitisa rare but serious adverse effect
Several local providers have pharmaceutical research backgrounds, which means they approach GLP-1 prescribing from a clinical data perspective rather than a trends-and-marketing one
These medications, widely prescribed for diabetes and weight loss, have been linked to severe side effects, prompting a surge in legal action
The average age of GLP-1 medication users in the UK is 44 years , with people aged 40-59 making up more than half of users (53.5%)
doi: 10.1161/CIRCULATIONAHA.118.036418 42 MarsoS
.png.jpg)
